Terns Pharmaceuticals, Inc. (TERN) closed the last trading session at $38.52, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $58.13 indicates a 50.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $5.19. While the lowest estimate of $54.00 indicates a 40.2% increase from the current price level, the most optimi ...

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as one of the 11 best-performing stocks over the past 12 months [1] Group 1: Strategic Developments - Terns Pharmaceuticals has amended its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd., converting a non-exclusive, royalty-free license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701, excluding the Hansoh Territory [2] - The company will pay a one-time upfront license fee of $1.0 million and tiered royalties of 0.75%-1.25% on annual net sales of TERN-701 products, with potential reductions applicable [3] Group 2: Analyst Sentiment - Citizens has raised its price target for Terns Pharmaceuticals from $35 to $57, maintaining an 'Outperform' rating, reflecting positive sentiment based on the interim Phase 1 CARDINAL ASH update showcasing TERN-701's strong profile and response rates [4] Group 3: Company Focus - Terns Pharmaceuticals specializes in developing small-molecule and combination therapies targeting NASH, oncology, and chronic liver disease, with clinical-stage programs focused on FXR, VAP-1, THR-β, and GLP-1 [5]

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as one of the top 14 stocks to buy currently, with a Buy rating and a price target of $56 from Truist Financial analyst Srikripa Devarakonda [1] - The stock's price target was raised from $35 to $56 following positive Phase 1 study results for TERN-701, aimed at treating chronic myeloid leukemia (CML) [2] - The study demonstrated a 64% major molecular response rate at 24 weeks, indicating strong efficacy and safety, which has led to a bullish outlook from analysts [3] Analyst Ratings - Mizuho Securities also maintains an Outperform rating on Terns Pharmaceuticals with a price target of $54, viewing TERN-701 as a potential best-in-disease treatment for CML [3] - The consensus among Wall Street analysts is a Strong Buy rating, with shares having increased over 300% in the last three months [4] - Analysts project an additional upside of 42.31%, based on a one-year average share price target of $53.75 [4] Company Overview - Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious diseases, including cancer and obesity [5] - The company aims to initiate pivotal trials for TERN-701 by the end of 2026, as stated by CEO Amy Burroughs [4]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - Terns has had a successful year in 2025 and anticipates continued excitement in 2026, with the potential to become a best-in-disease therapy in the CML market [3] - The company has demonstrated unprecedented efficacy along with a strong safety and tolerability profile, positioning itself for the next generation of CML therapies [3] - Terns plans to engage with the FDA to discuss trial design and aims to initiate second-line and first-line trials promptly [4] Financial Position - Terns currently holds $1 billion in cash on its balance sheet, providing a strong financial foundation for upcoming trials and initiatives [4]

Summary of Terns Pharmaceuticals FY Conference Call Company Overview - **Company**: Terns Pharmaceuticals (NasdaqGS:TERN) - **Event**: FY Conference Call on January 12, 2026 - **Key Speakers**: Amy Burroughs (CEO), Emil Kuriakose (CMO), Scott Harris (CDO) [1] Industry Context - **Industry**: Chronic Myeloid Leukemia (CML) treatment - **Current Market Dynamics**: - CML was previously a fatal disease until the introduction of BCR-ABL inhibitors like Gleevec (Imatinib) in 2001 - Asiminib, an allosteric inhibitor, gained a 22% market share in the front-line treatment within three quarters of its approval in November 2024 [4][5] Core Points and Arguments - **Performance in 2025**: Terns had a successful year and anticipates continued success in 2026, aiming to establish itself as a leader in CML therapy [2] - **Financial Position**: Terns has $1 billion in cash, alleviating financing concerns until commercial launch [3] - **Efficacy of Terns 701**: - Terns 701 shows unprecedented efficacy with a 75% major molecular response (MMR) rate in a highly refractory patient population [6][9] - Deep molecular response (DMR) rate of 36% at recommended doses [7] - Comparison with Asiminib indicates Terns 701 may outperform in both efficacy and safety [10][20] - **Safety Profile**: - No dose-limiting toxicities observed; majority of adverse events were low-grade [9][11] - Terns 701 does not exhibit the pancreatic toxicity (20%) or hypertension (18%) seen with Asiminib [5][6] - Administered once daily without food restrictions, enhancing patient convenience [9][26] Market Opportunities - **Potential for Terns 701**: - Positioned as a next-generation therapy with better efficacy and safety compared to existing treatments [10][25] - Anticipated to capture significant market share in the front-line treatment of CML [25][26] - **Regulatory Pathway**: - Plans to engage with the FDA for trial design and dose selection in 2026 [22][29] - A second-line plus trial is expected to be initiated, with confidence in achieving MMR as a primary endpoint [22][23] Additional Insights - **Patient Population**: - High baseline disease burden among trial participants, with 64% showing lack of efficacy to previous treatments [12][13] - Notable patient cases demonstrate Terns 701's effectiveness in individuals resistant to Asiminib [18][19] - **Future Directions**: - Terns plans to open a mutation cohort for patients with specific mutations, enhancing the understanding of Terns 701's efficacy [21] - Additional data releases and longer-term safety studies are anticipated in 2026 [26][27] Conclusion - Terns Pharmaceuticals is positioned to make significant advancements in CML treatment with Terns 701, backed by strong efficacy and safety data, a solid financial foundation, and strategic regulatory plans for 2026 [27]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned to profit from the surge in electricity demand driven by AI data centers [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It has a unique footprint in nuclear energy, which is considered vital for America's future power strategy [7][14] Financial Health - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines without the associated premium costs [9][10] Market Sentiment - There is a growing interest from Wall Street in this company, as it is seen as undervalued and capable of delivering real cash flows while owning critical infrastructure [8][10] - The company is trading at less than 7 times earnings, making it an attractive investment opportunity in the context of AI and energy [10][11] Future Outlook - The influx of talent into the AI sector is expected to drive rapid advancements and innovation, reinforcing the notion that investing in AI is backing the future [12][13] - The combination of AI infrastructure needs, energy demands, and the onshoring boom presents a unique investment landscape that this company is well-positioned to navigate [14][15]

Financial Position - Terns Pharmaceuticals has approximately $1.0 billion in cash, cash equivalents, and marketable securities as of year-end 2025, expected to provide a runway into 2031[1]. - Terns completed a public offering of 18,687,500 shares, generating gross proceeds of approximately $747.5 million before expenses[7]. Clinical Trials and Drug Development - The CARDINAL Phase 1/2 trial of TERN-701 is enrolling well, with over 85 patients enrolled as of December 8, 2025[7]. - TERN-701 achieved a major molecular response (MMR) rate of 75% (18/24) by 24 weeks in evaluable patients at the recommended phase 2 dose range of >320mg QD, significantly higher than asciminib[7]. - The company plans to select a pivotal dose for TERN-701 in mid-2026 and initiate a pivotal trial in late 2026 or early 2027[3]. - TERN-701 has been granted U.S. FDA Fast Track designation for the treatment of chronic myeloid leukemia (CML) in Q4 2025[1]. - The company aims to generate data that strengthens TERN-701's position as a potential best-in-disease therapy across all lines of CML treatment[2]. - The majority of treatment-emergent adverse events (TEAEs) in the CARDINAL trial were low grade, with no dose-limiting toxicities observed[3]. - Updated and expanded CARDINAL data is expected to be released in the second half of 2026[3]. Strategic Partnerships - The company is seeking a strategic partner to advance the TERN-501 and TERN-801 legacy metabolic programs[7].

Core Insights - Terns Pharmaceuticals is advancing its lead program TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), with significant milestones planned for 2026 [1][3][8] - The company has reported strong enrollment in the CARDINAL Phase 1/2 trial and aims to initiate pivotal trials by late 2026 or early 2027 [1][2][3] - Terns has a robust financial position with approximately $1.0 billion in cash and marketable securities, expected to sustain operations into 2031 [1][8] Milestones and Clinical Development - Key milestones for TERN-701 in 2026 include pivotal dose selection and an End of Phase 2 regulatory interaction with the U.S. FDA [1][3] - The initiation of the first pivotal trial targeting the 2L+ patient population is anticipated in late 2026 or early 2027 [1][3] - The trial design includes evaluating TERN-701 against a control arm of second-generation TKIs, with major molecular response (MMR) at six months as the primary endpoint [3] Clinical Data and Efficacy - At the 67th ASH Annual Meeting, TERN-701 demonstrated a 75% MMR achievement rate by 24 weeks in evaluable patients, significantly higher than previous treatments [8] - The safety profile of TERN-701 is encouraging, with 87% of patients remaining on treatment and no dose-limiting toxicities observed [3][8] - The majority of treatment-emergent adverse events were low grade, with grade 3 or higher events occurring in less than 10% of patients [3] Financial Position and Corporate Updates - Terns completed a public offering in December 2025, raising approximately $747.5 million, enhancing its financial stability [8] - The company is exploring strategic partnerships to advance its legacy metabolic programs, TERN-501 and TERN-801 [8] - Terns is committed to rapidly advancing TERN-701 towards product launch to maximize its therapeutic and commercial potential [2]

Group 1 - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is recognized as a top performer, with a remarkable increase of 629.64 percent in 2025, driven by positive clinical trial results for its therapy candidate targeting chronic myeloid leukemia (CML) [1][2] - The therapy candidate, TERN-701, demonstrated a 64 percent improvement in the conditions of 63 enrolled CML patients after 24 weeks of treatment [1][2] - A major molecular response rate of 74 percent was observed at a higher dosage of 320 mg among the trial participants [2] Group 2 - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares to the public, with funds allocated for the development and commercial launch of TERN-701 [2] - The remaining proceeds from the fundraising will be utilized for working capital and other general corporate purposes [2]